Answer
Patients receiving Zypadhera should be monitored for hyperglycaemia symptoms such as polydipsia, polyuria, polyphagia and weakness.
Sources for this answer
- ZYPADHERA 210 mg, 300 mg and 405 mg powder and solvent for prolonged release suspension for injectionNeon Healthcare Ltd · emc · SmPC §4.4 Special warnings and precautions for use · Version 2Document updated
Sources checked